Pioneer Pharma (singapore) Pte. Ltd. - Net Worth and Insider Trading

Pioneer Pharma (singapore) Pte. Ltd. Net Worth

The estimated net worth of Pioneer Pharma (singapore) Pte. Ltd. is at least $244 dollars as of 2024-11-13. Pioneer Pharma (singapore) Pte. Ltd. is the 10% Owner of NovaBay Pharmaceuticals Inc and owns about 313 shares of NovaBay Pharmaceuticals Inc (NBY) stock worth over $244. Details can be seen in Pioneer Pharma (singapore) Pte. Ltd.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Pioneer Pharma (singapore) Pte. Ltd. has not made any transactions after 2015-03-03 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Pioneer Pharma (singapore) Pte. Ltd.

Pioneer Pharma (singapore) Pte. Ltd. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Pioneer Pharma (singapore) Pte. Ltd. owns 1 companies in total, including NovaBay Pharmaceuticals Inc (NBY) .

Click here to see the complete history of Pioneer Pharma (singapore) Pte. Ltd.’s form 4 insider trades.

Insider Ownership Summary of Pioneer Pharma (singapore) Pte. Ltd.

Ticker	Comapny	Transaction Date	Type of Owner
NBY	NovaBay Pharmaceuticals Inc	2015-03-03	10 percent owner

Pioneer Pharma (singapore) Pte. Ltd. Latest Holdings Summary

Pioneer Pharma (singapore) Pte. Ltd. currently owns a total of 1 stock. Pioneer Pharma (singapore) Pte. Ltd. owns 313 shares of NovaBay Pharmaceuticals Inc (NBY) as of March 3, 2015, with a value of $244.

Latest Holdings of Pioneer Pharma (singapore) Pte. Ltd.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
NBY	NovaBay Pharmaceuticals Inc	2015-03-03	313	0.78	244

Holding Weightings of Pioneer Pharma (singapore) Pte. Ltd.

Pioneer Pharma (singapore) Pte. Ltd. Form 4 Trading Tracker

According to the SEC Form 4 filings, Pioneer Pharma (singapore) Pte. Ltd. has made a total of 0 transactions in NovaBay Pharmaceuticals Inc (NBY) over the past 5 years. The most-recent trade in NovaBay Pharmaceuticals Inc is the acquisition of 85 shares on March 3, 2015, which cost Pioneer Pharma (singapore) Pte. Ltd. around $2 Million.

Insider Trading History of Pioneer Pharma (singapore) Pte. Ltd.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Pioneer Pharma (singapore) Pte. Ltd. Trading Performance

GuruFocus tracks the stock performance after each of Pioneer Pharma (singapore) Pte. Ltd.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Pioneer Pharma (singapore) Pte. Ltd. is 9.09%. GuruFocus also compares Pioneer Pharma (singapore) Pte. Ltd.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Pioneer Pharma (singapore) Pte. Ltd. within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Pioneer Pharma (singapore) Pte. Ltd.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Pioneer Pharma (singapore) Pte. Ltd.

Average Return

Average return per transaction

Outperforming Transactions

1 out of 3 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	17.71
Relative Return to S&P 500(%)	17.68

Pioneer Pharma (singapore) Pte. Ltd. Ownership Network

Ownership Network List of Pioneer Pharma (singapore) Pte. Ltd.

No Data

Ownership Network Relation of Pioneer Pharma (singapore) Pte. Ltd.

Pioneer Pharma (singapore) Pte. Ltd. Owned Company Details

What does NovaBay Pharmaceuticals Inc do?

Who are the key executives at NovaBay Pharmaceuticals Inc?

Pioneer Pharma (singapore) Pte. Ltd. is the 10 percent owner of NovaBay Pharmaceuticals Inc. Other key executives at NovaBay Pharmaceuticals Inc include Interim CFO Tommy Law , President & DERMAdoctor & LLC Jeffrey Kunin , and Chief Product Officer Audrey Kunin .

NovaBay Pharmaceuticals Inc (NBY) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NovaBay Pharmaceuticals Inc (NBY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NovaBay Pharmaceuticals Inc (NBY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NovaBay Pharmaceuticals Inc (NBY)'s detailed insider trading history can be found in Insider Trading Tracker table.

NovaBay Pharmaceuticals Inc Insider Transactions

No Available Data

Pioneer Pharma (singapore) Pte. Ltd. Mailing Address

Above is the net worth, insider trading, and ownership report for Pioneer Pharma (singapore) Pte. Ltd.. You might contact Pioneer Pharma (singapore) Pte. Ltd. via mailing address: 33a Chander Road, Singapore U0 219539.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.